Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 10/20 | 0.68 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.46 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081834 | 1.00 | LPAR3 (0.68) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL1739832 | 1.00 | LPAR3 (0.68) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11082621 | 0.92 | LPAR3 (0.57) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11079228 | 0.92 | LPAR3 (0.57) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11083607 | 0.91 | LPAR3 (0.56) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11091806 | 0.91 | LPAR3 (0.56) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11081544 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL4747959 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11088254 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11079136 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008118879-A2 | ANTIVIRAL COMPOSITIONS COMPRISING 2 COMPOUNDS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | PNP, TYMP, MTAP | LPAR3 1438/4885LPAR1 1211/4885LPAR2 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.